CONTEXT: Vitamin D deficiency disproportionately affects nonwhite individuals. Controversy persists over how to best restore low 25D levels, and how to best define vitamin D status [total (protein bound plus free) vs free 25D]. OBJECTIVE: To assess the effects of vitamin D3 (cholecalciferol, or D3) vs 25-hydroxyvitamin D3 (calcifediol, or 25D3) on total and free 25D in a multiethnic cohort of adults, and whether change in parathyroid hormone (PTH) is more strongly associated with total vs free 25D. DESIGN: Sixteen-week randomized controlled trial. Biochemistries at 0, 4, 8, and 16 weeks. SETTING: Academic medical center. PARTICIPANTS: Thirty-five adults ≥18 years of age with 25D levels <20 ng/mL. INTERVENTION: Sixty micrograms (2400 IU)/d of D3 or 20 μg/d of 25D3. MAIN OUTCOME MEASURES: Total and free 25D, and PTH. RESULTS: Baseline total (16.2 ± 3.7 vs 17.0 ± 2.5 ng/mL; P = 0.4) and free (4.2 ± 0.8 vs 4.7 ± 1.0 pg/mL; P = 0.2) 25D were similar between D3 and 25D3 groups, respectively; 25D3 increased total (+25.5 vs +13.8 ng/mL; P = 0.001) and free (+6.6 vs +3.5 pg/mL; P = 0.03) 25D more than D3. By 4 weeks, 87.5% of 25D3 participants had total 25D levels ≥30 ng/mL, compared with 23.1% of D3 participants (P = 0.001). Change in PTH was associated with both total (P = 0.01) and free 25D (P = 0.04). CONCLUSIONS: 25D3 increased total and free 25D levels more rapidly than D3, regardless of race/ethnicity. Free and total 25D were similarly associated with change in PTH.
CONTEXT: Vitamin D deficiency disproportionately affects nonwhite individuals. Controversy persists over how to best restore low 25D levels, and how to best define vitamin D status [total (protein bound plus free) vs free 25D]. OBJECTIVE: To assess the effects of vitamin D3 (cholecalciferol, or D3) vs 25-hydroxyvitamin D3 (calcifediol, or 25D3) on total and free 25D in a multiethnic cohort of adults, and whether change in parathyroid hormone (PTH) is more strongly associated with total vs free 25D. DESIGN: Sixteen-week randomized controlled trial. Biochemistries at 0, 4, 8, and 16 weeks. SETTING: Academic medical center. PARTICIPANTS: Thirty-five adults ≥18 years of age with 25D levels <20 ng/mL. INTERVENTION: Sixty micrograms (2400 IU)/d of D3 or 20 μg/d of 25D3. MAIN OUTCOME MEASURES: Total and free 25D, and PTH. RESULTS: Baseline total (16.2 ± 3.7 vs 17.0 ± 2.5 ng/mL; P = 0.4) and free (4.2 ± 0.8 vs 4.7 ± 1.0 pg/mL; P = 0.2) 25D were similar between D3 and 25D3 groups, respectively; 25D3 increased total (+25.5 vs +13.8 ng/mL; P = 0.001) and free (+6.6 vs +3.5 pg/mL; P = 0.03) 25D more than D3. By 4 weeks, 87.5% of 25D3 participants had total 25D levels ≥30 ng/mL, compared with 23.1% of D3 participants (P = 0.001). Change in PTH was associated with both total (P = 0.01) and free 25D (P = 0.04). CONCLUSIONS: 25D3 increased total and free 25D levels more rapidly than D3, regardless of race/ethnicity. Free and total 25D were similarly associated with change in PTH.
Authors: John Aloia; Ruban Dhaliwal; Mageda Mikhail; Albert Shieh; Alexandra Stolberg; Louis Ragolia; Melissa Fazzari; Steven A Abrams Journal: J Clin Endocrinol Metab Date: 2015-08-27 Impact factor: 5.958
Authors: N Binkley; D Gemar; J Engelke; R Gangnon; R Ramamurthy; D Krueger; M K Drezner Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: Pauline M Camacho; Steven M Petak; Neil Binkley; Bart L Clarke; Steven T Harris; Daniel L Hurley; Michael Kleerekoper; E Michael Lewiecki; Paul D Miller; Harmeet S Narula; Rachel Pessah-Pollack; Vin Tangpricha; Sunil J Wimalawansa; Nelson B Watts Journal: Endocr Pract Date: 2016-09 Impact factor: 3.443
Authors: J B Schwartz; J Lai; B Lizaola; L Kane; S Markova; P Weyland; N A Terrault; N Stotland; D Bikle Journal: J Clin Endocrinol Metab Date: 2014-01-31 Impact factor: 5.958
Authors: S Lundgren; T Carling; G Hjälm; C Juhlin; J Rastad; U Pihlgren; L Rask; G Akerström; P Hellman Journal: J Histochem Cytochem Date: 1997-03 Impact factor: 2.479
Authors: Camille E Powe; Catherine Ricciardi; Anders H Berg; Delger Erdenesanaa; Gina Collerone; Elizabeth Ankers; Julia Wenger; S Ananth Karumanchi; Ravi Thadhani; Ishir Bhan Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: Ishir Bhan; Camille E Powe; Anders H Berg; Elizabeth Ankers; Julia B Wenger; S Ananth Karumanchi; Ravi I Thadhani Journal: Kidney Int Date: 2012-03-07 Impact factor: 10.612
Authors: Albert Shieh; S Melanie Lee; Venu Lagishetty; Carter Gottleib; Jonathan P Jacobs; John S Adams Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 6.134
Authors: Albert Shieh; Christina Ma; Rene F Chun; Jonas Wittwer-Schegg; Leon Swinkels; Tonnie Huijs; Jeffrey Wang; Ines Donangelo; Martin Hewison; John S Adams Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 6.134